Aeluma, Inc. (ALMU) is a Goleta, California-based semiconductor company developing compound-semiconductor photonics for AI datacom, sensing, defense, and quantum applications. Three current, attributable analyst targets form the basis of the $21 central figure used here: Freedom Capital Markets holds a Buy rating with a $25 target (lowered from $30 in September 2026), Craig-Hallum reiterates a Buy with a $22 target, and Northland initiated coverage with an Outperform rating and a $16 target. The arithmetic mean of these three figures is $21, with a low-to-high range of $16 to $25.
That range is wide, and it tells the real story. All three analysts see meaningful upside from current levels, but they disagree sharply on magnitude. The more cautious view (Northland, $16) reflects the reality that Aeluma is still transitioning away from government R&D contracts toward commercial sales. The more bullish figures ($22 and $25) place greater weight on the company's scalable non-indium-phosphide manufacturing approach, its CHIPS Act engagement, and the large projected market for photonics in AI data centers.
Aeluma closed at $7.58 on November 12, 2026, giving the stock a market capitalization near $139 million. Its 52-week range is $5.87 to $31.79, which highlights how volatile the shares have been as investors reprice an early-stage company shifting its strategy. Reaching $21 from $7.58 would require a gain of roughly 177%, a very large move that would likely demand not just improving sentiment but concrete evidence of commercial traction.
The path toward such a level would probably run through customer design wins and non-recurring engineering (NRE) agreements, qualification of its high-speed photodetectors and quantum dot lasers, and progress on converting a CHIPS Act letter of intent into a definitive funding agreement. Because the company is pre-profit and generating only modest contract revenue, valuation is driven far more by milestones and narrative than by current earnings multiples.
Several verified developments underpin the bull case. Aeluma has signed a letter of intent for up to $30 million in proposed CHIPS and Science Act funding to advance its scalable photonics platform. It has executed strategic agreements with Sumitomo Chemical Advanced Technologies for wafer production and with AIXTRON for a 200 mm-capable MOCVD (metalorganic chemical vapor deposition) system to expand manufacturing. Management cites expanding customer discussions tied to an anticipated 2028–2032 AI infrastructure buildout, and the company held roughly $53.9 million in cash as of September 30, 2026, providing runway to fund development.
The obstacles are substantial and verified. First-quarter fiscal 2027 revenue fell to about $0.6 million from $1.4 million a year earlier, and the net loss widened to $3.8 million, or $0.19 per share. Full fiscal 2026 revenue declined to roughly $4.46 million. Freedom Capital Markets specifically noted that the company did not provide a fiscal 2027 revenue range, citing that omission as a reason for its target cut. Execution risk in commercializing photonics, competition from larger players such as Lumentum and Coherent, and the possibility that design wins convert to volume more slowly than bulls expect are all meaningful hurdles.
The stock trades far below its 52-week high of $31.79 and near the lower end of its range, with the $5.87 low acting as a key long-term support area. The shares would need to reclaim the psychological $10 level and then the mid-teens before the $21 target becomes a live technical consideration. Until a sustained base forms above the recent lows, the long-term structure remains defined more by recovery potential than by confirmed breakout.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state the exact window. Investors should monitor the conversion of the CHIPS Act letter of intent into a definitive agreement, new customer or NRE announcements, quarterly revenue trajectory, and whether management begins providing forward revenue guidance. Sumitomo and AIXTRON milestone progress and broader AI-datacom capital spending will also matter.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile, news-sensitive name like Aeluma, the tool can help traders surface opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning. Traders exploring the AI Daily Buy/Sell Signals page can use these signals to support their own research process.
The $21 target is the arithmetic mean of three current analyst targets ranging from $16 to $25. From a $7.58 close, reaching it would require a very large move of roughly 177%. The bull case rests on the AI-datacom photonics opportunity, potential CHIPS Act funding, and strategic manufacturing partnerships; the bear case rests on shrinking revenue, widening losses, and unproven commercial conversion. The unusually wide analyst range shows genuine uncertainty, and whether Aeluma approaches $21 will depend on verifiable commercial milestones rather than sentiment alone.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALMU has been loosely correlated with MRAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ALMU jumps, then MRAM could also see price increases.
| Ticker / NAME | Correlation To ALMU | 1D Price Change % | ||
|---|---|---|---|---|
| ALMU | 100% | -9.81% | ||
| MRAM - ALMU | 55% Loosely correlated | -16.36% | ||
| GSIT - ALMU | 51% Loosely correlated | -10.32% | ||
| AIP - ALMU | 47% Loosely correlated | -12.74% | ||
| AOSL - ALMU | 46% Loosely correlated | -15.32% | ||
| NVTS - ALMU | 46% Loosely correlated | -15.20% | ||
More | ||||